Virtus Biotech Clinical Trials ETF (BBC)
Score for how it compares with the broader market is near the bottom of its range.
BBC scores higher than 12% of the 5,673 tickers we compare it with (Funds & ETFs).
As of 9 October 2026, Virtus Biotech Clinical Trials ETF (BBC) scores 39 out of 100 on the Market Census six-factor composite, which puts it at the Below average score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 9 October 2026, and it is not investment advice.
Updated · scores usually change about once a day
Key statistics
Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.
- Relative volume
- 0.29× 30-day average
- 52-week range
- 28.35 – 56.18
- Market cap
- —
- Earnings date
- —
- Volume
- 5,323
- Avg. volume (30d)
- 18,144
- Open
- 42.95
- Previous close
- 43.24
- Day's range (regular session)
- 42.95 – 44.42
The last trade can be an extended-hours trade, so it can sit outside the regular-session range.
Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.
- Beta
- 0.93
- P/E (TTM)
- —
- EPS (TTM)
- —
Score breakdown · six named factors
Each bar is one part of the score, from 0 to 100. Read what the score means.
What the score says about BBC right now
Virtus Biotech Clinical Trials ETF (BBC) currently scores 39/100 on the Market Census six-factor composite, at the Below average score level. BBC is +2.08% on the day and -0.97% over five sessions as of the most recent tick. Below average sits a bit below the middle. More of BBC's data reads poorly than well. The level is a "look before you act" flag. It is not advice. BBC's strongest factor is company finances at 54/100 — a fairly good read on the company's own reported numbers. A high reading doesn't promise a near-term move. The weakest factor is strength vs the market at 14/100 — well below average next to the wider market.
Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.
See BBC in the scanner
This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).
Recent BBC news
No recent headlines name Virtus Biotech Clinical Trials ETF.
Saved snapshot; the news and prices on this page can be an hour old or more.
Similar setups in Funds & ETFs right now
Six funds & etfs tickers whose composite scores are closest to BBC’s 39, all within 1 point.
Sorted by closeness to BBC’s composite score within Funds & ETFs. Saved snapshot; can be an hour old or more. Run the full scanner →
Prices delayed about 15 minutes; scores usually change about once a day. Not investment advice — see risk disclosure.